Gilead Sciences and Arcus Biosciences said Monday that an experimental cancer immunotherapy directed against a target called TIGIT reduced the risk of tumor progression or death by 45% in a mid-stage clinical trial involving patients with lung cancer.
The new data for the drug called domvanalimab were not tested for statistical significance and will need to be confirmed in a larger, Phase 3 study, but the preliminary results will likely be seen as a boost to the ongoing partnership between Gilead and the smaller biotech Arcus, established in 2020.
The domvanalimab results also represent a comeback of sorts for the entire class of TIGIT-targeted antibody treatments, which took a hit earlier this year following setbacks for Roche and its own anti-TIGIT compound.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
